Investor interest in biopharma company Amarin (NASDAQ: AMRN) mounted this summer as the company gained approval from the Food and Drug Administration for its triglyceride-lowering drug, Vascepa. In an effort to help investors examine both the bull and bear cases for this stock, we've put together a brand new premium research report on Amarin that examines the company's market opportunity, biggest threats, and reasons to both buy and sell today.
In the following video, Austin Smith talks with health care analyst Max Macaluso about why this drug has garnered so much attention, what Vascepa actually does, and the competition that Amarin could soon face once this new medication reaches patients.
Austin Smith has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.